Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children

NCT01254175 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

NIH

Sponsor class

Conditions

Parainfluenza Virus 3, Human

Interventions

BIOLOGICAL: rHPIV3cp45 Vaccine
BIOLOGICAL: Placebo Vaccine

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)